Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College were awarded a $3.3 million grant over five years by the National Cancer Institute to use artificial intelligence (AI) to improve targeted drug therapy in HER2-positive breast cancer treatment. HER2-positive breast cancer tends to grow and spread quickly, but targeted treatments improve outcomes.
Credit: Rensselaer Polytechnic Institute and Albany Medical College
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College were awarded a $3.3 million grant over five years by the National Cancer Institute to use artificial intelligence (AI) to improve targeted drug therapy in HER2-positive breast cancer treatment. HER2-positive breast cancer tends to grow and spread quickly, but targeted treatments improve outcomes.
The research is being led by Xavier Intes, Rensselaer professor of biomedical engineering and co-director of the Center for Modeling, Simulation and Imaging in Medicine, and Margarida Barroso, a professor of molecular and cellular physiology and director of the Imaging Core Facility at Albany Medical College. RPI and Albany Medical College have collaborated continuously for over a decade focusing on treatments to improve human health supported by six major grants. This grant propels that collaboration forward using modern AI tools.
Targeted drugs are an important part of many cancer therapies to improve specificity and reduce negative side effects. However, resistance to targeted therapy often occurs, preventing long-term, disease-free survival in many patients.
This grant will fund research in HER2-positive breast cancer where it has been proposed that intratumor heterogeneity (ITH), in which cells within the same tumor have different profiles, and microenvironmental factors play a key role in treatment failure. Hence, a better understanding of the underlying mechanisms of HER2 therapy resistance and their relationship with ITH, as well as with the host and tumor microenvironments, is essential for the development of new strategies to improve patient outcomes.
Preclinical longitudinal, non-invasive imaging approaches that can dissect and quantify heterogeneities at the level of multiple tumor features such as drug-HER2 engagement, glucose metabolic levels, and vasculature are lacking. Currently, these parameters can only be assessed through ex-vivo invasive means, using tissue removed from and then returned to the patient.
“Through our research, we will develop a novel mesoscopic, multimodal preclinical imaging approach to test the hypothesis that the distribution of antibody-based therapeutics across tumors mediates not only drug efficacy but also the advent of tumor resistance,” said Intes.
The team will use mesoscopic fluorescence molecular tomography (MFMT) to dissect tumor heterogeneities at near cellular scale resolution in live, intact animals.
Barroso will also collaborate with Sandra Shin, MD, chair of the Department of Pathology and Laboratory Medicine at Albany Medical Center, to correlate histopathology with these novel optical imaging approaches.
“Ultimately, we hope this imaging technology will allow biologists and clinicians to see exactly how a drug binds to a tumor, providing a better understanding of how tumors adapt or change during treatment,” said Barroso. “This could help determine a particular drug’s efficacy on a specific tumor, a key element of tackling drug resistance.”
“For more than a decade, NCI has been recognizing the importance of this cross-institutional collaboration and the unique skills and expertise each researcher brings to the collaboration,” added Alan S. Boulos, MD, ’94, The Lynne and Mark Groban, MD ’67 Dean of Albany Medical College. “The studies supported by this new grant will have a significant impact on the future of cancer diagnostics and therapy.”
“Breast cancer is such a prevalent disease that we all know someone affected by it,” said Shekhar Garde, dean of Rensselaer’s School of Engineering. “I am pleased that Drs. Intes and Barroso are combining the power of engineering and medicine with modern artificial intelligence tools to advance our understanding of this particularly virulent form and improve patients’ quality of life.”
About Rensselaer Polytechnic Institute
Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, over 30 research centers, more than 140 academic programs including 25 recent programs, and a dynamic community made up of over 6,800 students and 104,000 living alumni. Rensselaer faculty and alumni include upward of 155 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit www.rpi.edu.
About Albany Medical Center
Albany Medical Center, northeastern New York’s only academic medical center, is one of the largest private employers in the Capital Region. It incorporates the 766-bed Albany Medical Center, which offers the widest range of medical and surgical services in the region, and Albany Medical College, which trains the next generation of doctors, scientists, and other healthcare professionals. It also includes the region’s largest physicians’ practice with 500 doctors. Albany Medical Center works with dozens of community partners to improve the region’s health and quality of life. Albany Medical Center is a member of the Albany Med Health System, which also includes Columbia Memorial Health, Glens Falls Hospital, Saratoga Hospital, and the Visiting Nurses. The region’s largest locally governed health system, it has 1,520 beds, more than 800 physicians and 125 outpatient locations throughout the Capital Region.
RPI Contact:
Katie Malatino
Sr. Communications Specialist
[email protected]
838-240-5691
Albany Medical Center Contact:
Cassie Nelson
Manager of Communications
[email protected]
518-262-3421
###